Fig. 5. Effect of DATS administration on the expression of genes and proteins associated with mitogen-activated protein kinase (MAPK) pathways in the mammary tumors of rats. (A) Quantification of MAPK3, MAPK9, and MAPK14 levels in RNA-seq data. Results shown are mean ± SD (n = 3). (B) Immunoblots for ERK1, JNK2, p38, and β-actin in tumor lysates from control and DATS-treated rats. (C) Quantification of the expression of the proteins shown in (B). Results shown are mean ± SD (n = 6 for both groups). (D) Immunoblots for phospho-ERK, phospho-JNK, phospho-p38, and GAPDH in tumor lysates from control and DATS-treated rats. (E) Quantification of the expression of the phospho-proteins shown in (D). Results shown are mean ± SD (n = 6 for both groups). ERK1, extracellular-signal-related kinase 1; FPKM, the expected number of Fragments Per Kilobase of transcript sequence per Millions base pairs sequenced; DATS, diallyl trisulfide; JNK2, c-Jun N-terminal kinase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *Significantly different compared with control (P < 0.05) by unpaired Student’s t-test.

© J Cancer Prev